1-3 of 3
Jing Liang, MD
Close
Sort by
Journal Articles

Clinical Activity of a Novel Multiple Tyrosine Kinase and Aurora Kinase Inhibitor, ENMD-2076, Against Multiple Myeloma: Interim Phase I Trial Results

Sherif Farag, MD, PhD, Shuhong Zhang, PhD, Attaya Suvannasankha, MD, Jing Liang, MD, Robyn O'Bryant, RN, Wood Lisa, RN, Sushil Gupta, PhD, Mark Bray, PhD, Carolyn Fowler Sidor, MD, Rafat Abonour, MD
Journal: Blood
Blood (2010) 116 (21): 1957.
https://doi.org/10.1182/blood.V116.21.1957.1957
Published: 2010
Journal Articles

The Novel Aurora Kinase Inhibitor ENMD-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in Vitro and in Vivo , and Shows Synergistic Activity in Combination with Lenalidomide

Xiaojing Wang, PhD, Anthony L. Sinn, Attaya Suvannasankha, MD, Colin D. Crean, Li Chen, MD, Shuhong Zhang, PhD, Jing Liang, MD, Genglin Zhang, Karen E. Pollok, PhD, Rafat Abonour, MD, Carolyn Sidor, MD, Mark R. Bray, PhD, Sherif S. Farag, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3660.
https://doi.org/10.1182/blood.V112.11.3660.3660
Published: 2008
Journal Articles

Unlike Inactivating PTEN Mutations, Pharmacological Inhibition of PTEN Does Not Increase the Sensitivity of Multiple Myeloma Cells to Inhibition of the PI3K/Akt/mTOR Pathway.

Xiaojing Wang, PhD, Shuhong Zhang, Ph.D, Xiaodong Peng, Ph.D, Joe Garlich, Ph.D, Li Chen, MD, Jing Liang, MD, Sherif Shafik Farag, MD, Ph.D
Journal: Blood
Blood (2007) 110 (11): 4785.
https://doi.org/10.1182/blood.V110.11.4785.4785
Published: 2007